{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:03:01Z","timestamp":1790161381189,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Hypercalcemia of malignancy (HCM) is associated with poor short-term prognosis, particularly when it represents the initial manifestation of an underlying, as yet uncharacterized malignancy. Serum calcium concentration alone may not adequately capture the systemic biological burden associated with advanced disease. Methods: In this retrospective, single-center cohort study, 71 patients with moderate-to-severe hypercalcemia (corrected calcium \u226512 mg\/dL) in whom a hematologic or solid malignancy was subsequently diagnosed were evaluated. The modified Endothelial Activation and Stress Index (m-EASIX = LDH \u00d7 CRP\/platelet count) was calculated at presentation. Univariate and multivariable logistic regression, receiver operating characteristic (ROC) analysis and Kaplan\u2013Meier survival analysis were used to evaluate the association between Log2 m-EASIX and 90-day mortality. Results: Log2 m-EASIX remained independently associated with 90-day mortality in multivariable analysis (adjusted OR = 1.96, 95% CI 1.37\u20132.82, p &lt; 0.001), whereas white blood cell count and albumin did not reach statistical significance in the same model. Corrected serum calcium was not associated with mortality (p = 0.702). Log2 m-EASIX showed good discriminative performance (AUC = 0.857, 95% CI 0.768\u20130.946) and stratified 90-day survival in both hematologic (p &lt; 0.001) and solid malignancies (p = 0.002), with no significant interaction between m-EASIX and malignancy subgroup (p = 0.499). Conclusions: m-EASIX, calculated from routinely available laboratory parameters, may provide clinically useful prognostic information for early risk stratification in patients presenting with hypercalcemia of malignancy.<\/jats:p>","DOI":"10.3390\/jcm15197382","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:20:46Z","timestamp":1790155246000},"page":"7382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of the Modified Endothelial Activation and Stress Index (m-EASIX) for 90-Day Mortality in Patients with Moderate-to-Severe Hypercalcemia of Malignancy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-2482","authenticated-orcid":false,"given":"Nevriye G\u00fcl","family":"Ada Tak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Bursa Buyukorhan Integrated State Hospital, Bursa 16990, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-3791","authenticated-orcid":false,"given":"Hikmet","family":"\u00d6ztop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-9830","authenticated-orcid":false,"given":"Faz\u0131l \u00c7a\u011fr\u0131","family":"Hunutlu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Bursa City Training and Research Hospital, University of Health Sciences, Bursa 16280, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: A review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: An update","volume":"97","author":"Wysolmerski","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, pathophysiology and management of hypercalcemia in malignancy: A review of the literature","volume":"51","author":"Asonitis","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_5","first-page":"496","article-title":"Hypercalcemia of Malignancy","volume":"9","author":"Feldenzer","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11912-025-01685-z","article-title":"Acute Management of Hypercalcemia of Malignancy\u2014A Review of Pathophysiology, Diagnosis, and Treatment","volume":"27","author":"Crouch","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.47582\/jompac.1834647","article-title":"Corrected calcium as a predictor of short-term mortality in patients hospitalized with cancer-related hypercalcemia","volume":"6","author":"Aydemir","year":"2025","journal-title":"J. Med. Palliat. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JGO.2016.006890","article-title":"Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes","volume":"3","author":"Ramos","year":"2017","journal-title":"J. Glob. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: An Endocrine Society clinical practice guideline","volume":"108","author":"Clines","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/jth.15880","article-title":"Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer","volume":"20","author":"Moik","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: A retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20406207251387409","DOI":"10.1177\/20406207251387409","article-title":"Clinical practice of the endothelial activation and stress index and its modified versions in multiple myeloma and the effects on prognosis","volume":"17","author":"Gursoy","year":"2026","journal-title":"Ther. Adv. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cavdar, V.C., Gokmen, Y., Aric, M., Altunkaya, T., Erdem, C.G., Gulturk, I., and Afsar, C.U. (2025). The prognostic value of the EASIX score in patients with metastatic pancreatic cancer. Diagnostics, 15.","DOI":"10.3390\/diagnostics15141740"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Park, S., Go, S.I., and Lee, G.W. (2022). The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09915-4"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yan\u0131k, A.M., Sadri, S., \u015ean, A.B., G\u00fcl, \u00d6.\u00d6., and \u00d6zkalemka\u015f, F. (2026). Time-Dependent Prognostic Value of the mEASIX Score in Patients with Myelodysplastic Syndromes. Diagnostics, 16.","DOI":"10.3390\/diagnostics16111640"},{"key":"ref_16","first-page":"377","article-title":"Hypercalcemia and cancer: Differential diagnosis and treatment","volume":"68","author":"Zagzag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7861\/clinmed.2023-0227","article-title":"Treatment of hypercalcaemia of malignancy in adults","volume":"23","author":"Drake","year":"2023","journal-title":"Clin. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1210\/jc.2014-4250","article-title":"PTHrP-Mediated Hypercalcemia: Causes and Survival in 138 Patients","volume":"100","author":"Donovan","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","first-page":"e35783","article-title":"Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergency","volume":"15","author":"Gupta","year":"2023","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1731942","DOI":"10.1080\/2162402X.2020.1731942","article-title":"Lactate dehydrogenase: A marker of diminished antitumor immunity","volume":"9","author":"Koornstra","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"Franco","year":"2015","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moreno-Casta\u00f1o, A.B., Fern\u00e1ndez, S., Brillembourg, H., Iraola, G., Moreno, D.F., Ventosa-Capell, H., Martinez-Sanchez, J., De Moner, B., Molina, P., and Ramos, A. (2026). M-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1664788"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Song, G.Y., Jung, S.H., Kim, K., Kim, S.J., Yoon, S.E., Lee, H.S., Kim, M., Ahn, S.Y., Ahn, J.S., and Yang, D.H. (2020). Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07317-y"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hunutlu, F.\u00c7., \u00d6ztop, H., G\u00fcrsoy, V., Ersal, T., Elg\u00fcn, E., Yavuz, \u015e., Ekizo\u011flu, S.\u0130., Ekizo\u011flu, A.A., \u00d6zkocaman, V., and \u00d6zkalemka\u015f, F. (2025). Modified endothelial activation and stress index: A new predictor for survival outcomes in classical Hodgkin lymphoma treated with doxorubicin-bleomycin-vinblastine-dacarbazine-based therapy. Diagnostics, 15.","DOI":"10.3390\/diagnostics15020185"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/CBM-220032","article-title":"Endothelial activation and stress index (EASIX) as a predictive biomarker in small cell lung cancer","volume":"35","author":"Go","year":"2022","journal-title":"Cancer Biomark."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4111\/icu.20220204","article-title":"Prognostic value of the endothelial activation and stress index in patients with upper tract urothelial cancer undergoing radical nephroureterectomy","volume":"63","author":"Gu","year":"2022","journal-title":"Investig. Clin. Urol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:02:27Z","timestamp":1790157747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197382"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197382","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}